Back to Current Sarcoma Research

ASSG Endorsed Clinical Study

ASSG16-CASPS

Title A Phase II Trial of Cediranib in the Treatment of
Patients with Alveolar Soft Part Sarcoma
(CASPS)
Objective The primary objective of this study is to evaluate the efficacy of cediranib in the treatment of
ASPS by measuring the percentage change in the sum of target marker lesion diameters
from randomisation to week 24 (or progression if sooner) compared to treatment with
placebo.
Type Double-blind, placebo-controlled clinical trial
Population Male and female patients, 16+ yrs with histologically confirmed ASPS
Treatment Deiranib 30mg daily po vs placebo
Phase Ph II
Drug / Intervention Deiranib 30mg daily po vs placebo
Sponsor The Institute of Cancer Research
Funding Source Cancer Research UK, AstraZenenca, ASSG
Target accrual AUS: 9
Expected Completion 15/12/2020
Participating Sites AUS: Lifehouse, Princess Alexandra
Recruitment Status Closed to accrual
Numbers Accrued 5
Publications and Presentations None as reported
 
Principal Investigator AUS: Dr Martin Tattersall
Contact for Further Information PAH: Dr Warren Joubert
Lifehouse: Dr Vivek Bhadri
Contact Phone Number PAH: Dr Warren Joubert (07 3176 6577), warren_joubert@health.qld.gov.au
Lifehouse: Dr Vivek Bhadri (02-85140749), vivek.bhadri@lh.org.au
Last update 01-Sep-2017 03:52 PM 

 

biospecimen
Clinical  Data
Contact ASSG